ICON Reports First Quarter 2018 Results

Highlights from the quarter include:

– ICON Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution
– ICON opens a new office in Boston
– Excluding the impact of ASC 606, net business wins in the quarter were $590 million; a book to bill of 1.28.
– Excluding the impact of ASC 606, closing backlog of $5,053 million, an increase of 17.2% year on year.
– Quarter 1 reported revenue of $620.1 million. Excluding the impact of ASC 606, quarter 1 revenue was $462.6 million, representing a 7.1% increase year on year.
– Reported income from operations was $91.7 million, or 14.8% of revenue. Excluding the impact of ASC 606 income from operations was $92.8 million or 20.1% of revenue.
– Reported earnings per share of $1.42. Excluding the impact of ASC 606, earnings per share of $1.44, an 11.6% increase year on year.
– Earnings guidance increased by $0.02 to reflect quarter 1 share repurchases to $5.91 – $6.11. Revenue guidance reconfirmed in the range of $2,520 – $2,640 million.

Read More

Almac Group Appoints David Taylor as Head of Manufacturing Operations

N.I., 01 May 2018 – David Taylor joined the Almac Group in November 2017 as Head of Manufacturing, Almac Sciences.  He is tasked with the overall accountability for small molecule API and peptide manufacturing in Craigavon, and delivering on Almac’ Sciences’ supply chain operations at the Northern Ireland site.  David has worked in the pharmaceutical and fine chemical industries for over twenty-two years, and brings with him a strong background in both the technical and manufacturing disciplines, allowing him to lead multidisciplinary teams to deliver streamlined operational outcomes. In an industry with significant emphasis on safety, quality and regulatory compliance, David has the skill set needed to anticipate and successfully communicate planning and procurement changes to customers, clients and third-parties abroad.

Read More